MRI of inducible P-selectin expression in human activated platelets involved in the early stages of atherosclerosis

✍ Scribed by Marie-Josée Jacobin-Valat; Kamel Deramchia; Stéphane Mornet; Christoph E. Hagemeyer; Stéphane Bonetto; Rémy Robert; Marc Biran; Philippe Massot; Sylvain Miraux; Stéphane Sanchez; Anne-Karine Bouzier-Sore; Jean-Michel Franconi; Etienne Duguet; Gisèle Clofent-Sanchez

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 603 KB
• Volume: 24
• Category: Article
• ISSN: 0952-3480
• DOI: 10.1002/nbm.1606

✦ Synopsis

Abstract

The noninvasive imaging of atherosclerotic plaques at an early stage of atherogenesis remains a major challenge for the evaluation of the pathologic state of patients at high risk of acute coronary syndromes. Recent studies have emphasized the importance of platelet–endothelial cell interactions in atherosclerosis‐prone arteries at early stages, and the prominent role of P‐selectin in the initial loose contact between platelets and diseased vessel walls. A specific MR contrast agent was developed here for the targeting, with high affinity, of P‐selectin expressed in large amounts on activated platelets and endothelial cells. For this purpose, PEGylated dextran/iron oxide nanoparticles [PEG, poly(ethylene glycol)], named versatile ultrasmall superparamagnetic iron oxide (VUSPIO) particles, labeled with rhodamine were coupled to an anti‐human P‐selectin antibody (VH10). Flow cytometry and microscopy experiments on human activated platelets were highly correlated with MRI (performed at 4.7 and 0.2 T), with a 50% signal decrease in T~2~ and T~1~ values corresponding to the strong labeling of activated vs resting platelets. The number of 1000 VH10–VUSPIO nanoparticles attained per activated platelet appeared to be optimal for the detection of hypo‐ and hyper‐signals in the platelet pellet on T~2~‐ and T~1~‐weighted MRI. Furthermore, in vivo imaging of atherosclerotic plaques in ApoE mice at 4.7 T showed a spatial resolution adapted to the imaging of intimal thickening and a hypo‐signal at 4.7 T, as a result of the accumulation of VH10–VUSPIO nanoparticles in the plaque. Our work provides support for the further assessment of the use of VH10–VUSPIO nanoparticles as a promising imaging modality able to identify the early stages of atherosclerosis with regard to the pertinence of both the target and the antibody‐conjugated contrast agent used. Copyright © 2010 John Wiley & Sons, Ltd.